A Study to Evaluate the Denosumab in Healthy Adults
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Denosumab Injection Administered Subcutaneously to Healthy Adults in China
Sponsor: Luye Pharma Group Ltd.
Listed as NCT03427853, this PHASE1 trial focuses on Healthy Adults and remains ongoing. Sponsored by Luye Pharma Group Ltd., it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Dec 2021 — Mar 2022 [monthly]
Unknown Status PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Unknown Status PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Unknown Status PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Luye Pharma Group Ltd.
- Shandong Boan Biotechnology Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .